On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist Lantheus is placing some serious cash on the dealmaking table. In a ...

In addition, the radiopharmaceutical is prepared in a formulation matrix that maintains chemical stability during manufacturing and shipping. How do scientists choose which radioisotope to use, and ...

A live webcast will be available for the TD Cowen 45 th Annual Health Care Conference and Leerink Global Healthcare Conference presentations on the Investors section of the Company’s website at ...

The IAEA also supports the development of clinical nuclear medicine services by assisting Member States in setting up reliable radiopharmaceutical production facilities for single photon emission ...

AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector continues in 2025. The funding round was co-led by SV Health Investors, ...

As revenues rose for Novartis’ radiopharmaceutical blockbuster Pluvicto, competitors are packing their pipelines with radiopharmaceuticals through acquisitions and licencing deals, hoping to ...

Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical ... Don't miss out on Boston-area life science news. Subscribe to the Morning Edition ...

Evergreen is a clinical-stage radiopharmaceutical company that offers Contract Development and Manufacturing (CDMO) services, drug discovery, and the commercialization of proprietary products.

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35 th Annual Healthcare Life Sciences Conference. Dr. Andrew ...

Radiopharmaceutical manufacturing will be offered as a hybrid format through the Indianapolis campus and will reward a master ...

Scientists at the University of Wisconsin Madison and Dana-Farber Cancer Institute recently presented preclinical data for the radiopharmaceutical therapy candidate [177Lu]PNT-6555.